Drug Trial Radar · NCT02480374
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Sep 2015
Primary completion
May 2017
Study completion May 2017
Sponsor
- Lead sponsor
- ImunonIndustry
- Sponsor type
- Industry
- First posted
- Jun 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
IMNN-001Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: 4 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Birmingham Cancer Center
Birmingham, Alabama
Washington Univ. in St. Louis/Barnes Jewish Hospital
St Louis, Missouri
Stephenson Cancer Center
Oklahoma City, Oklahoma
Medical College of Wisconsin/Froedtert Hospital
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.